Human papillomavirus antibody response following HAART initiation among MSM.

Details

Serval ID
serval:BIB_43A9C92AD28E
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Human papillomavirus antibody response following HAART initiation among MSM.
Journal
AIDS
Author(s)
Combes J.D., Clifford G.M., Egger M., Cavassini M., Hirsch H.H., Hauser C., Calmy A., Schmid P., Bernasconi E., Günthard H.F., Franceschi S., Waterboer T., Scherrer A.U.
Working group(s)
Swiss HIV Cohort Study
ISSN
1473-5571 (Electronic)
ISSN-L
0269-9370
Publication state
Published
Issued date
20/02/2017
Peer-reviewed
Oui
Volume
31
Number
4
Pages
561-569
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
To describe effects of HAART on high-risk human papillomavirus (HPV) antibody response in HIV-positive MSM and the meaning of this response for subsequent HPV-related cancer risk.
Prospective seroepidemiological study of 281 HIV-positive MSM initiating HAART between 1995 and 2004 in the Swiss HIV Cohort Study.
For each individual, two serum samples, one at HAART initiation (pre-HAART) and another 24 months later (post-HAART), were tested for L1 antibodies to HPV6, 11, 16, 18, 31, 33, 35, 45, 52 and 58, as well as HPV16-E6 antibodies, using a multiplex serology assay. Identification of HPV-related cancer included data linkage with Swiss cancer registries.
Pre-HAART, 45.2% were seropositive for any high-risk HPV-L1 and 32.4% for HPV16-L1. Sexual intercourse during the last 6 months was the only evaluated factor associated with L1 seropositivity pre-HAART. Seropositivity increased post-HAART to 60.5% for any high-risk HPV-L1 [prevalence ratio versus pre-HAART = 1.34, 95% confidence interval (CI) 1.14-1.57] and 48.0% for HPV16-L1 (prevalence ratio versus pre-HAART = 1.48, 95% CI 1.20-1.83), and seroconversion was significantly associated with both lower CD4 cell count and CD4/CD8 ratio (P < 0.01). Only one individual was HPV16-E6-seropositive pre-HAART, but two more seroconverted post-HAART. Anal cancer incidence among the three HPV16-E6-positives post-HAART was significantly increased compared with HPV16-E6-negatives (incidence rate ratio = 63.1, 95% CI 1.1-1211).
HAART-related immune reconstitution increases HPV-specific antibody responses, which may discriminate future anal cancer risk in this high-risk population.

Keywords
Adult, Aged, Anti-Retroviral Agents/therapeutic use, Antibodies, Viral/blood, Antibody Formation, Antiretroviral Therapy, Highly Active, HIV Infections/drug therapy, Homosexuality, Male, Humans, Immune Reconstitution, Male, Middle Aged, Papillomavirus Infections/epidemiology, Papillomavirus Infections/immunology, Prospective Studies, Seroepidemiologic Studies, Switzerland/epidemiology, Young Adult
Pubmed
Web of science
Create date
30/01/2017 18:27
Last modification date
20/08/2019 13:47
Usage data